These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
507 related articles for article (PubMed ID: 18167109)
1. Evaluation of neoadjuvant prednisone administration and surgical excision in treatment of cutaneous mast cell tumors in dogs. Stanclift RM; Gilson SD J Am Vet Med Assoc; 2008 Jan; 232(1):53-62. PubMed ID: 18167109 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 cases (1998-2004). Mullins MN; Dernell WS; Withrow SJ; Ehrhart EJ; Thamm DH; Lana SE J Am Vet Med Assoc; 2006 Jan; 228(1):91-5. PubMed ID: 16426175 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of a two-centimeter lateral surgical margin for excision of grade I and grade II cutaneous mast cell tumors in dogs. Fulcher RP; Ludwig LL; Bergman PJ; Newman SJ; Simpson AM; Patnaik AK J Am Vet Med Assoc; 2006 Jan; 228(2):210-5. PubMed ID: 16426187 [TBL] [Abstract][Full Text] [Related]
4. Association of histologic tumor characteristics and size of surgical margins with clinical outcome after surgical removal of cutaneous mast cell tumors in dogs. Schultheiss PC; Gardiner DW; Rao S; Olea-Popelka F; Tuohy JL J Am Vet Med Assoc; 2011 Jun; 238(11):1464-9. PubMed ID: 21627510 [TBL] [Abstract][Full Text] [Related]
5. Use of histologic margin evaluation to predict recurrence of cutaneous malignant tumors in dogs and cats after surgical excision. Scarpa F; Sabattini S; Marconato L; Capitani O; Morini M; Bettini G J Am Vet Med Assoc; 2012 May; 240(10):1181-7. PubMed ID: 22559107 [TBL] [Abstract][Full Text] [Related]
6. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours. Kiupel M; Webster JD; Miller RA; Kaneene JB J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909 [TBL] [Abstract][Full Text] [Related]
7. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). Sauerbrey ML; Mullins MN; Bannink EO; Van Dorp TE; Kaneene JB; Obradovich JE J Am Vet Med Assoc; 2007 Jun; 230(12):1866-9. PubMed ID: 17571992 [TBL] [Abstract][Full Text] [Related]
8. Chlorambucil and prednisolone chemotherapy for dogs with inoperable mast cell tumours: 21 cases. Taylor F; Gear R; Hoather T; Dobson J J Small Anim Pract; 2009 Jun; 50(6):284-9. PubMed ID: 19527421 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of outcome associated with subcutaneous and intramuscular hemangiosarcoma treated with adjuvant doxorubicin in dogs: 21 cases (2001-2006). Bulakowski EJ; Philibert JC; Siegel S; Clifford CA; Risbon R; Zivin K; Cronin KL J Am Vet Med Assoc; 2008 Jul; 233(1):122-8. PubMed ID: 18593321 [TBL] [Abstract][Full Text] [Related]
11. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739 [TBL] [Abstract][Full Text] [Related]
12. Lomustine for treatment of mast cell tumors in cats: 38 cases (1999-2005). Rassnick KM; Williams LE; Kristal O; Al-Sarraf R; Baez JL; Zwahlen CH; Dank G J Am Vet Med Assoc; 2008 Apr; 232(8):1200-5. PubMed ID: 18412534 [TBL] [Abstract][Full Text] [Related]
13. Hypotonic water as adjuvant therapy for incompletely resected canine mast cell tumors: a randomized, double-blind, placebo-controlled study. Brocks BA; Neyens IJ; Teske E; Kirpensteijn J Vet Surg; 2008 Jul; 37(5):472-8. PubMed ID: 18986315 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of proliferating cell nuclear antigen and Ki-67 in mast cell tumors from dogs. Abadie JJ; Amardeilh MA; Delverdier ME J Am Vet Med Assoc; 1999 Dec; 215(11):1629-34. PubMed ID: 14567425 [TBL] [Abstract][Full Text] [Related]
16. Clinical outcome for MCTs of canine pinnae treated with surgical excision (2004-2008). Schwab TM; Popovitch C; DeBiasio J; Goldschmidt M J Am Anim Hosp Assoc; 2014; 50(3):187-91. PubMed ID: 24659731 [TBL] [Abstract][Full Text] [Related]
17. Electrochemotherapy compared to surgery for treatment of canine mast cell tumours. Kodre V; Cemazar M; Pecar J; Sersa G; Cor A; Tozon N In Vivo; 2009; 23(1):55-62. PubMed ID: 19368125 [TBL] [Abstract][Full Text] [Related]
18. Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006). Bannink EO; Sauerbrey ML; Mullins MN; Hauptman JG; Obradovich JE J Am Vet Med Assoc; 2008 Aug; 233(3):446-51. PubMed ID: 18673031 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of a modified proportional margins approach for surgical resection of mast cell tumors in dogs: 40 cases (2008-2012). Pratschke KM; Atherton MJ; Sillito JA; Lamm CG J Am Vet Med Assoc; 2013 Nov; 243(10):1436-41. PubMed ID: 24171373 [TBL] [Abstract][Full Text] [Related]